via www.medgadget.com
To help address the global obesity epidemic, scientists are developing a new class of compounds called “micelle sequestrant polymers,” or MSPs, that could prevent fat particles from getting absorbed in the body and thus potentially reduce weight gain. They report on their novel agents, which they tested on mice, in the ACS journal Biomacromolecules.
Research has shown that worldwide, obesity rates have been climbing for years. Treatments for overweight and obesity include diet and exercise, surgery and prescription medications. But currently available drugs can have serious side effects, including increased risk of cardiovascular disease and depression. So Cory Berkland and colleagues set out to find new kinds of pharmaceuticals to fight weight gain.
Targeting the body’s process of absorbing fat, the researchers designed a class of polymers that capture fat particles called micelles in the intestines so they can’t be digested. Instead, they pass through the gut and are excreted. In tests, mice who took these MSPs had nine to 10 times the amount of triglycerides — the main dietary fat — in their feces than the control animals. Additionally, because the MSPs pass through the body unabsorbed, the researchers say they could provide a safe approach for long-term treatment.
The Latest on: Antiobesity Drug
[google_news title=”” keyword=”Antiobesity Drug” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Antiobesity Drug
- Novo Nordisk to launch popular anti-obesity drug Wegovy in Japanon November 25, 2023 at 3:11 am
The monthly cost for patients will be 7,504 Japanese yen ($50.15) for a 0.25-milligram starter dose and 42,960 yen for a 2.4 mg dose, Novo said.
- Novo Nordisk spends big in France to expand obesity drug capacityon November 23, 2023 at 5:45 pm
Danish pharmaceutical giant Novo Nordisk on Thursday announced a major investment in a French production site to expand capacity including for a blockbuster anti-obesity drug.
- Ozempic maker plans manufacturing blitz as market for the drug is expected to top $100 billion in 2030on November 23, 2023 at 2:08 pm
Novo Nordisk announced two seperate investments in the past two weeks as it races to meet global demand for its hit anti-obesity drugs.
- Novo to launch anti-obesity drug Wegovy in Asia with February Japan roll-outon November 23, 2023 at 1:21 pm
Novo Nordisk will launch its hugely popular anti-obesity drug Wegovy in Japan on Feb. 22 next year, its first launch in Asia, the company said on Thursday, even as it struggles to keep up with demand ...
- Novo to debut weight-loss drug Wegovy in Asia with Japan launchon November 23, 2023 at 1:08 am
COPENHAGEN (Reuters) — Novo Nordisk will launch its hugely popular anti-obesity drug Wegovy in Japan on Feb. 22 next year, its first launch in Asia, the company said on Thursday, even as it struggles ...
- Indian pharma cos speed up anti-obesity drug development amid high demand, surge in Ozempic’s saleson November 21, 2023 at 9:52 am
Sun Pharma, Dr. Reddy's, Lupin, Torrent, and Zydus Cadila progressing obesity drug candidates in response to rising demand. Notable developments include Sun Pharma's Phase 1 studies and Dr. Reddy’s La ...
- New anti-obesity drugs approved, but still out of reach for many Black Americanson November 20, 2023 at 4:59 am
By Deborah Bailey, AFRO Contributing Editor, [email protected] A new class of weight loss medications are bringing hope to the more than 70 percent of Americans who are classified as medically ...
- Black patients have less access to anti-obesity drugs, data showson November 18, 2023 at 2:06 pm
According to data, while Black people are much more likely to suffer from obesity and diabetes, white people are four times more likely to get a prescription.
- Black People Are Facing Greater Challenges Accessing Anti-Obesity Drugs Like Ozempic and Wegovyon November 15, 2023 at 10:04 am
Diabetes and obesity disproportionately impact Black people, yet they are facing greater challenges gaining access to GLP-1 medications like Ozempic that could help treat these conditions.
- Popular Anti-Obesity Drug Could Have Yet Another Potential Health Benefiton November 14, 2023 at 2:00 pm
Originally developed to treat diabetes, semaglutide is now famous for its weight-loss properties. New research points to yet another potential benefit – boosting heart health.
via Bing News
